

Adlai Nortye acquires global rights to Novartis cancer drug

11 July 2018 | News

Adlai Nortye will have exclusive development and commercialization rights to buparlisib worldwide for all the therapeutic, prophylactic and/or diagnostic uses in humans.



China based Adlai Nortye Biopharma Co., Ltd., a biopharmaceutical company dedicated to discovering and commercializing new drugs in the field of oncology/immuno-oncology, has announced that it has entered into a Global License Agreement with Novartis Pharma AG, a global pharmaceutical company.

Under the terms of the Agreement, except for certain rights maintained by Novartis Pharma AG, Adlai Nortye will have exclusive development and commercialization rights to buparlisib worldwide for all the therapeutic, prophylactic and/or diagnostic uses in humans.

Buparlisib (BKM120) is an oral pan-PI3K inhibitor that targets all class 1 PI3K isoforms and is active in both hematologic malignancies and solid tumors. It has shown promising efficacy in combination with paclitaxel in head and neck squamous cell carcinoma (HNSCC) and has received a Fast-Track designation from the FDA.